Analysis of T cell subsets in this response revealed that most tumor infiltrating T cells were CD8+, although CD4+ cells were also elevated in vMyx-IL15Rα-tdTr treated tumors compared to controls (Figure 6). The gene discussed is CD4; the disease is neoplasm.